---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316947"
form_type: "8-K"
ticker: "NOVT"
cik: "0001076930"
company_name: "NOVANTA INC"
filed_at: "2026-07-27T12:15:15+00:00"
generated_at: "2026-07-27T12:20:18.155393+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Novanta completes $1.2B acquisition of Riverpoint Medical; expects $0.18-$0.25 adjusted EPS accretion in 2027

## Summary
- Acquired Riverpoint Medical for ~$1.2B cash at closing; additional $250M milestone payment due by Jan 8, 2027.
- Funded with $616M in borrowings under credit facilities; total consolidated debt now $854.7M.
- Deal expected to double recurring medical consumables revenue to ~$300M and push medical end-market to 60% of total revenue.
- Expects $0.18-$0.25 adjusted EPS accretion in 2027, high single-digit ROIC by year three, and immediate accretion to margins.
- Riverpoint is a category leader in minimally invasive surgical consumables for sports medicine, trauma, and cardiovascular applications.

## SEC filing metadata
- accession: 0001193125-26-316947
- form_type: 8-K
- ticker: NOVT
- cik: 0001076930
- company_name: NOVANTA INC
- filed_at: 2026-07-27T12:15:15+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1076930/000119312526316947/0001193125-26-316947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1076930/000119312526316947/novt-20260722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316947
- JSON: https://secwatch.observer/filing/0001193125-26-316947.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.